Secondary malignancies in pediatric patients after hematopoietic stem cell transplantation
Authors:
L. Géczová 1,2; S. Šufliarska 2; J. Horáková 2; B. Mladosievičová 1; doc. MUDr. Prednosta Ústavu M. Bernadič, CSc.; mim. prof.
Authors place of work:
Oddelenie klinickej patofyziológie, Ústav patologickej fyziológie LFUK, Bratislavavedúca doc. MUDr. B. Mladosievičová, CSc.
1; Klinika detskej hematológie a onkológie LFUK a DFNsP, Transplantačná jednotka kostnej drene, Bratislavaprednostka doc. MUDr. E. Kaiserová
2
Published in the journal:
Čes-slov Pediat 2013; 68 (1): 49-56.
Category:
Review
Summary
There is an increased risk of early and late complications following allogeneic hematopoietic stem cell transplantation despite its demonstrated success in children. Among the life-threatening complications, which occur between 6 months and several years following the transplantation and the first diagnosis of malignancy, are secondary leukemias or secondary solid tumours.
In this review we summarise relevant genetic polymorphisms associated with increased risk of secondary malignancies. Additionally, we pay specific attention to screening, management and prophylaxis in pediatric patients following hematopoietic stem cell transplantation.
Key words:
hematopoietic stem cell transplantation, secondary malignancies, genetic polymorphisms
Zdroje
1. Šufliarska S, Horáková J, Boďová I. Transplantácie krvotvorných buniek v pediatrickej onkológii. Onkológia (Bratislava) 2006; 1 (2): 93–97.
2. Horáková J, Lukáč J, Šufliarska S, et al. Transplantácia krvotvorných buniek u detí. Čes-slov Pediat 2006; 61 (10): 610–616.
3. Savani BN, Griffith ML, Jagasia S, et al. How I treat late effects in adults after allogeneic stem cell transplanta-tion. Blood 2011 Mar 17; 117 (11): 3002–3009.
4. Lowe T, Bhatia S, Somlo G. Second malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13 (10): 1121–1134.
5. Socié G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000 Jan; 18 (2): 348–357.
6. Roziakova L, Bojtarova E, Mistrik M, et al. Secondary malignancies after hematopoietic stem cell transplantation. Neoplasma 2011; 58 (1): 1–8.
7. Socié G, Baker KS, Bhatia S. Subsequent malignant neo-plasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012 Jan; 18 (1): 139–150.
8. Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 2011 Aug; 4 (4): 437–454.
9. Socié G, Rizzo JD. Second solid tumors: Screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol 2012 Jan; 49 (1): 4–9.
10. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011 Jun 1; 29 (16): 2230–2239.
11. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010 Feb 20; 28 (6): 1011–1016.
12. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007 Nov 15; 110 (10): 3784–3792.
13. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001 Jan 15; 19 (2): 464–471.
14. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006; 37: 249–261.
15. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996 May 1; 87 (9): 3633–3639.
16. Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009 Jan 29; (5): 1175–1183.
17. Fenske TS, McMahon Ch, Edwin D, et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res 2006 May 15; 66 (10): 5029–5038.
18. Khan FM, Sy S, Louie P, et al. Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with history of chronic graft-versus-host disease, and rare in nasal mucosa. Blood 2010 Sep 9; 116 (10): 1803–1806.
19. Ding Y, Sun C-L, Li L, et al. Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair. Blood Cancer Journal (2012) 2, e58; doi:10.1038/bcj.2012.4.
20. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008 Aug 1; 112 (3): 741–749.
21. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatement-related leukemia. Proc Natl Acad Sci USA 1998 October 27; 95 (22): 13176–13181.
22. Pedersen-Bjergaard J, Klarskov Andersen M, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000 Jun 1; 95 (11): 3273–3279.
23. Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 2011 Oct; 20 (10): 2048–2067.
24. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytoge-netic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003 Jul 1; 102 (1): 43–52.
25. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 2007 Feb 10; 25 (5): 493–500.
26. http://www.sukl.sk.
27. Mladosievičová B, a kol. Kardioonkológia. 1. vyd. Bratislava: SAP, 2012: 34–36.
28. Mladosievičová B, Kaiserová E, Foltinová A. Možné neskoré následky protinádorovej liečby v detstve. 1. vyd. Bratislava: SAP, 2007: 107–109.
29. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004 Apr 15; 10 (8): 2675–2680.
30. Smith MT, Wang Y, Kane E, et al. Low NAD(P)H: quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 2001 Mar 1; 97 (5):1422–1426.
31. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999 Jul 15; 94 (2): 803–807.
32. Allan JM, Wild ChP, Willett EV, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001 September 25; 98 (20): 11592–11597.
33. Ye Z, Song H. Glutathione s-transferase polymor-phisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukemia: A systematic review and meta-analysis. Eur J Cancer 2005 May; 41 (7): 980–989.
34. Peffault de Latour R, Lévy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004 Mar 1; 103 (5): 1618–1624.
35. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005 May 15; 105 (10): 3802–3811.
36. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 27 March 1997; 336 (13): 897–904.
37. Children’s oncology group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, version 3,0 – October 2008.
38. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003 Apr 1; 21 (7): 1352–1358.
39. Faraci M, Békássy AN, De Fazio V, et al. Non-endocrine late complications in children after allogeneic hematopoietic SCT. Bone Marrow Transplant 2008 Jun; 41 (Suppl 2): S49–57.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2013 Číslo 1
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- A massive pulmonary embolism as a first symptom of nephrotic syndrome in 18-years old female patient
- Somatic development of the child and injury incidence during the pubertal spurt – new knowledge of the correlation between growth dynamics and injury risk in the present population of children
- Analysis of risk factors concerning suicidal behavior in childhood and adolescence
- Secondary malignancies in pediatric patients after hematopoietic stem cell transplantation